EMCURE Stock Overview
Engages in the developing, manufacturing, and marketing pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Emcure Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,305.95 |
| 52 Week High | ₹1,408.70 |
| 52 Week Low | ₹1,261.05 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMCURE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.6% | 2.2% | -1.0% |
| 1Y | n/a | 46.7% | 43.6% |
Return vs Industry: Insufficient data to determine how EMCURE performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how EMCURE performed against the Indian Market.
Price Volatility
| EMCURE volatility | |
|---|---|
| EMCURE Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: EMCURE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EMCURE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 10,852 | Satish Mehta | www.emcure.com |
Emcure Pharmaceuticals Limited engages in the developing, manufacturing, and marketing pharmaceutical products worldwide. It offers products in various therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV antivirals, respiratory, gastrointestinal, pain and analgesics, blood related, oncology/anti-neoplastics, anti-diabetic, hormones, neurology/central nervous system, and other areas, as well as vitamins, minerals, and nutrients. The company also develops products across various platforms, including chiral molecules, complex APIs, orals, iron products, photo-chemistry products, liposomal and lyophilized injectables, high potency drugs, biotherapeutics, and novel drug delivery systems.
Emcure Pharmaceuticals Limited Fundamentals Summary
| EMCURE fundamental statistics | |
|---|---|
| Market cap | ₹247.37b |
| Earnings (TTM) | ₹4.98b |
| Revenue (TTM) | ₹66.58b |
49.6x
P/E Ratio3.7x
P/S RatioIs EMCURE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMCURE income statement (TTM) | |
|---|---|
| Revenue | ₹66.58b |
| Cost of Revenue | ₹25.36b |
| Gross Profit | ₹41.23b |
| Other Expenses | ₹36.24b |
| Earnings | ₹4.98b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 26.35 |
| Gross Margin | 61.92% |
| Net Profit Margin | 7.48% |
| Debt/Equity Ratio | 66.9% |
How did EMCURE perform over the long term?
See historical performance and comparison